BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24427336)

  • 1. Impact of polysomy 17 on HER2 testing of invasive breast cancer patients.
    Liu Y; Ma L; Liu D; Yang Z; Yang C; Hu Z; Chen W; Yang Z; Chen S; Zhang Z
    Int J Clin Exp Pathol; 2014; 7(1):163-73. PubMed ID: 24427336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.
    Vranic S; Teruya B; Repertinger S; Ulmer P; Hagenkord J; Gatalica Z
    Cancer; 2011 Jan; 117(1):48-53. PubMed ID: 20803611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
    J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high copy number of HER2 associated with polysomy 17 on HER2 protein expression in invasive breast carcinoma.
    Shah SS; Wang Y; Tull J; Zhang S
    Diagn Mol Pathol; 2009 Mar; 18(1):30-3. PubMed ID: 19214111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment and significance of human epidermal growth factor receptor 2 gene status in breast cancer with polysomy of chromosome 17].
    Zhang H; Si JW; Zhang S; Wang Y; Li D; Li T
    Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):124-9. PubMed ID: 26899332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB; de Weger RA; van Diest PJ
    Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
    Jiang H; Bai X; Zhao T; Zhang C; Zhang X
    Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
    Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
    Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study.
    Downs-Kelly E; Yoder BJ; Stoler M; Tubbs RR; Skacel M; Grogan T; Roche P; Hicks DG
    Am J Surg Pathol; 2005 Sep; 29(9):1221-7. PubMed ID: 16096413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of HER2 gene status in breast cancer with HER2 protein overexpression].
    Zeng X; Liang ZY; Wu SF; Zhou WX; Gao J; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):584-8. PubMed ID: 17134563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
    Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
    J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.
    Hanna WM; Rüschoff J; Bilous M; Coudry RA; Dowsett M; Osamura RY; Penault-Llorca F; van de Vijver M; Viale G
    Mod Pathol; 2014 Jan; 27(1):4-18. PubMed ID: 23807776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort.
    Koudelakova V; Trojanec R; Vrbkova J; Donevska S; Bouchalova K; Kolar Z; Varanasi L; Hajduch M
    Genes Chromosomes Cancer; 2016 May; 55(5):409-17. PubMed ID: 26847577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
    Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
    Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
    Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HER2 status in breast cancer of Chinese women: a study of 1170 cases using fluorescence in-situ hybridization].
    Zeng X; Liang ZY; Wu SF; Gao J; Zhou WX; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2008 Sep; 37(9):594-8. PubMed ID: 19094582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
    Orsaria M; Khelifa S; Buza N; Kamath A; Hui P
    J Clin Pathol; 2013 Dec; 66(12):1070-5. PubMed ID: 23908451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.